Adage Capital Partners GP L.L.C. Reduces Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Adage Capital Partners GP L.L.C. trimmed its position in Applied Therapeutics, Inc. (NASDAQ:APLT) by 52.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,961,629 shares of the company’s stock after selling 2,150,732 shares during the period. Adage Capital Partners GP L.L.C. owned about 1.69% of Applied Therapeutics worth $1,680,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics during the fourth quarter valued at approximately $35,000. Intech Investment Management LLC lifted its stake in shares of Applied Therapeutics by 176.1% during the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock worth $45,000 after purchasing an additional 33,567 shares during the period. Barclays PLC boosted its holdings in shares of Applied Therapeutics by 186.1% during the third quarter. Barclays PLC now owns 200,012 shares of the company’s stock worth $1,702,000 after purchasing an additional 130,102 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in shares of Applied Therapeutics by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock valued at $268,000 after purchasing an additional 47,983 shares during the period. Finally, Norges Bank acquired a new position in Applied Therapeutics in the fourth quarter valued at $208,000. 98.31% of the stock is owned by institutional investors and hedge funds.

Applied Therapeutics Trading Up 0.2 %

NASDAQ APLT opened at $0.39 on Wednesday. The business’s 50-day moving average price is $0.45 and its 200 day moving average price is $2.67. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62. The company has a market capitalization of $55.58 million, a PE ratio of -0.24 and a beta of 1.88.

Applied Therapeutics (NASDAQ:APLT) last announced its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million. Equities analysts predict that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.